Abiopharma

Goldman Sachs BDC Inc is a non-diversified closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and to a lesser extent capital appreciation primarily through direct originations of secured debt including the first lien unitranche and second lien debt and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The companys origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

Additional info from NASDAQ:
Goldman Sachs BDC Inc is a non-diversified closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and to a lesser extent capital appreciation primarily through direct originations of secured debt including the first lien unitranche and second lien debt and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The companys origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.